Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
Tel: |
400-9205774 |
Email: |
sales@glpbio.cn |
Products Intro: |
Product Name:Brimonidine-d4 CAS:1184971-51-4 Purity:>98% Package:1mg;10mg;50mg;100mg;
|
Company Name: |
Jinan blalong chemical co. LTD
|
Tel: |
2710913286@.com |
Email: |
1513643261@qq.com |
Products Intro: |
Product Name:Brimonidine-d4 CAS:1184971-51-4 Purity:99% HPLC Package:50G;10G;1G;500MG;100MG
|
Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
Tel: |
18818260767 |
Email: |
sales@chemegen.com |
Products Intro: |
Product Name:Brimonidine-d4 CAS:1184971-51-4 Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
Tel: |
021-65675885 18964387627 |
Email: |
customer_service@efebio.com |
Products Intro: |
Product Name:Brimonidine-d4 CAS:1184971-51-4 Purity:95.00% Package:500μg;1mg;5mg
|
|
| 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Basic information |
Product Name: | 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine | Synonyms: | 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine;5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d4)quinoxalin-6-amine | CAS: | 1184971-51-4 | MF: | C11H10BrN5 | MW: | 292.14 | EINECS: | | Product Categories: | | Mol File: | 1184971-51-4.mol | |
| 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Chemical Properties |
storage temp. | Store at -20°C | solubility | DMSO: soluble; Water: 1.5 mg/ml | form | A solid |
| 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Usage And Synthesis |
Description | Brimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine by GC- or LC-MS. Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).1 It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.2 It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.3 Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension. | References | 1. Munk, S.A., Harcourt, D.A., Arasasingham, P.N., et al. Synthesis and evaluation of 2-(arylamino)imidazoles as α2-adrenergic agonists J. Med. Chem. 40(1),18-23(1997). 2. Sawada, K., Hiraoka, M., and Ohguro, H. Effect of antiglaucoma medicine on intraocular pressure in DBA/2J mice Ophthalmic Res. 55(4),205-211(2016). 3. Lee, D., Kim, K.Y., Noh, Y.H., et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor A in ischemic retinal injury PLoS One 7(10),e47098(2012). |
| 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Preparation Products And Raw materials |
|